First personalised cancer vaccine cuts risk of disease returning in major trial (opens in a new tab)

bbc.com · 2026-10-23

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail

The story

First personalised cancer vaccine cuts risk of disease returning in major trial

bbc.com · 2026-10-23

The story’s checkable claims.

Read the original story

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Reading mode

Scan verdicts. Open evidence only when needed.

Claim 1 of 4Not checkedA personalised cancer vaccine given alongside the immunotherapy drug Keytruda cut the risk of patients dying or their skin cancer returning by 42% in a major clinical trial.View evidenceHide evidence

As stated42%

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 4Not checkedThe trial found the drug combination reduced the risk of melanoma spreading by 38% over two years compared with immunotherapy alone.View evidenceHide evidence

As stated38% over two years

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 4Not checkedThe study involved 1,137 adults, most of whom received Keytruda plus the experimental personalised vaccine while the rest received a placebo or dummy drug alongside immunotherapy.View evidenceHide evidence

As stated1,137 adults; about two-thirds received the vaccine

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 4Not checkedIndependent experts said the results were impressive but that longer-term studies are still needed to establish whether the treatment helps most patients live longer on average.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results